IL160659A0 - Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders - Google Patents

Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders

Info

Publication number
IL160659A0
IL160659A0 IL16065902A IL16065902A IL160659A0 IL 160659 A0 IL160659 A0 IL 160659A0 IL 16065902 A IL16065902 A IL 16065902A IL 16065902 A IL16065902 A IL 16065902A IL 160659 A0 IL160659 A0 IL 160659A0
Authority
IL
Israel
Prior art keywords
methods
disorders
antibodies
polypeptide antigens
mitotic
Prior art date
Application number
IL16065902A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL160659A0 publication Critical patent/IL160659A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL16065902A 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders IL160659A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31750401P 2001-09-05 2001-09-05
PCT/US2002/028176 WO2003020909A2 (en) 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders

Publications (1)

Publication Number Publication Date
IL160659A0 true IL160659A0 (en) 2004-08-31

Family

ID=23233944

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16065902A IL160659A0 (en) 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
IL160659A IL160659A (en) 2001-09-05 2004-03-01 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160659A IL160659A (en) 2001-09-05 2004-03-01 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation

Country Status (17)

Country Link
EP (1) EP1432446B1 (zh)
JP (2) JP5224632B2 (zh)
KR (3) KR20040044850A (zh)
CN (2) CN101446590A (zh)
AT (1) ATE506965T1 (zh)
AU (1) AU2002332838B2 (zh)
BR (1) BR0212641A (zh)
CA (1) CA2457541C (zh)
DE (1) DE60239881D1 (zh)
DK (1) DK1432446T3 (zh)
HU (1) HUP0500617A3 (zh)
IL (2) IL160659A0 (zh)
MX (1) MXPA04002084A (zh)
NZ (1) NZ531515A (zh)
PL (1) PL374363A1 (zh)
WO (1) WO2003020909A2 (zh)
ZA (1) ZA200401751B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SI1651162T1 (sl) * 2003-05-20 2016-02-29 Immunogen, Inc. Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NO347360B1 (no) * 2003-10-10 2023-09-25 Immunogen Inc Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse.
SG189730A1 (en) * 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
ES2309012T3 (es) * 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
WO2001055720A2 (en) * 2000-01-26 2001-08-02 Ventana Medical Systems, Inc. A system for developing assays for personalized medicine

Also Published As

Publication number Publication date
KR20090104925A (ko) 2009-10-06
DK1432446T3 (da) 2011-07-18
NZ531515A (en) 2007-11-30
ATE506965T1 (de) 2011-05-15
JP2010280691A (ja) 2010-12-16
ZA200401751B (en) 2005-07-27
EP1432446B1 (en) 2011-04-27
HUP0500617A2 (hu) 2005-10-28
WO2003020909A3 (en) 2003-11-20
KR20040044850A (ko) 2004-05-31
BR0212641A (pt) 2005-04-12
MXPA04002084A (es) 2004-06-07
JP5224632B2 (ja) 2013-07-03
EP1432446A4 (en) 2004-09-08
KR20100061863A (ko) 2010-06-09
PL374363A1 (en) 2005-10-17
JP2005517155A (ja) 2005-06-09
CN101446590A (zh) 2009-06-03
HUP0500617A3 (en) 2012-05-02
CA2457541A1 (en) 2003-03-13
EP1432446A2 (en) 2004-06-30
AU2002332838B2 (en) 2007-08-02
CA2457541C (en) 2013-01-08
CN1578673A (zh) 2005-02-09
DE60239881D1 (de) 2011-06-09
IL160659A (en) 2011-07-31
WO2003020909A2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
EP1551812A4 (en) MITOTIC KINESINE HEMMER
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESIN
EP0954340A4 (en) ASSOCIATED TARGET IMMUNOTHERAPY AGAINST CANCER
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2008091620A3 (en) Combination therapy comprising romidepsin and i.a. bortezomib
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2004089294A3 (en) Compositions, methods and kits relating to her-2 cleavage
WO2000051548A3 (en) COMPOSITIONS AND METHODS FOR THEIR PREPARATION FROM $i(LEPIDIUM)
WO2005065183A3 (en) Mitotic kinesin inhibitors
AU2002352708A1 (en) Cytotoxic agents
WO2004028474A3 (en) Caspase inhibitors as anticancer agents
WO2002080854A3 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL160659A0 (en) Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
MX2022013393A (es) Receptores de antígenos quiméricos dirigidos a cd19 y uso de los mismos.
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
MXPA03005374A (es) Carbazoles antitumorales.
WO2003077874A3 (en) Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2002026730A3 (en) Fluorinated quinolones as antimitotic and antitumor agents
WO2023201234A3 (en) Anti-variable muc1* antibodies and uses thereof